Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
0.7071
Dollar change
-0.0233
Percentage change
-3.19
%
IndexRUT P/E- EPS (ttm)-2.19 Insider Own15.00% Shs Outstand54.48M Perf Week-0.27%
Market Cap38.65M Forward P/E- EPS next Y-1.02 Insider Trans-1.01% Shs Float46.46M Perf Month-19.95%
Income-118.51M PEG- EPS next Q-0.40 Inst Own46.60% Short Float5.55% Perf Quarter24.05%
Sales20.97M P/S1.84 EPS this Y50.23% Inst Trans-0.34% Short Ratio3.96 Perf Half Y-45.19%
Book/sh1.05 P/B0.67 EPS next Y6.61% ROA-76.94% Short Interest2.58M Perf Year-82.75%
Cash/sh1.85 P/C0.38 EPS next 5Y- ROE-109.80% 52W Range0.50 - 4.67 Perf YTD-4.83%
Dividend Est.- P/FCF- EPS past 5Y-1.20% ROI-118.22% 52W High-84.86% Beta0.74
Dividend TTM- Quick Ratio4.43 Sales past 5Y115.17% Gross Margin69.32% 52W Low41.42% ATR (14)0.08
Dividend Ex-Date- Current Ratio4.54 EPS Y/Y TTM-37.39% Oper. Margin-579.43% RSI (14)42.14 Volatility8.04% 10.18%
Employees55 Debt/Eq0.76 Sales Y/Y TTM-49.92% Profit Margin-565.21% Recom1.40 Target Price5.12
Option/ShortYes / Yes LT Debt/Eq0.76 EPS Q/Q-5.19% Payout- Rel Volume0.28 Prev Close0.73
Sales Surprise-68.12% EPS Surprise-32.29% Sales Q/Q-7.88% EarningsMar 04 AMC Avg Volume651.03K Price0.71
SMA20-11.85% SMA50-13.23% SMA200-50.36% Trades Volume181,919 Change-3.19%
Date Action Analyst Rating Change Price Target Change
Mar-08-23Downgrade BofA Securities Neutral → Underperform $13 → $6
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Apr-02-24 07:00AM
Mar-07-24 07:00AM
06:40AM
Mar-05-24 09:07AM
07:51AM
08:51PM Loading…
Mar-04-24 08:51PM
05:10PM
04:21PM
04:01PM
Feb-12-24 04:01PM
Jan-22-24 10:19AM
07:00AM
Dec-18-23 07:00AM
Nov-14-23 11:04AM
08:48AM
06:00PM Loading…
Nov-13-23 06:00PM
04:15PM
04:01PM
Nov-09-23 11:38AM
Nov-06-23 10:00AM
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 02:53AM
Aug-08-23 05:54AM
Aug-07-23 05:15PM
04:09PM
04:01PM
Aug-03-23 07:00AM
07:00AM Loading…
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
02:00AM
May-16-23 11:02AM
May-15-23 05:15PM
04:07PM
04:01PM
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
10:02AM
09:43AM
08:05AM
Mar-06-23 07:39PM
05:15PM
04:01PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
04:01PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
08:15AM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
04:01PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
Jul-22-22 06:39AM
Jun-30-22 10:19AM
07:00AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Apr 05 '24Sale0.832,7532,28588,247Apr 09 04:21 PM
Goncalves JoanaCHIEF MEDICAL OFFICERApr 05 '24Sale0.832,7532,28553,365Apr 09 04:22 PM
Posner ChristopherPRESIDENT AND CEOFeb 29 '24Sale0.895,8345,192180,521Mar 04 04:19 PM
Goncalves JoanaCHIEF MEDICAL OFFICERFeb 29 '24Sale0.893,2932,93156,118Mar 04 04:13 PM
Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Feb 29 '24Sale0.893,2932,93191,000Mar 04 04:24 PM
Posner ChristopherPRESIDENT AND CEOFeb 08 '24Sale0.5335,57518,855186,355Feb 12 05:10 PM
Posner ChristopherPRESIDENT AND CEOFeb 01 '24Sale0.554,9812,740221,930Feb 05 04:26 PM
Posner ChristopherPresident and CEONov 02 '23Sale1.223,7964,631164,411Nov 03 04:37 PM
Posner ChristopherPresident and CEOAug 03 '23Sale3.074,30713,222168,207Aug 04 05:21 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJun 23 '23Sale3.512,99310,505153,747Jun 27 04:08 PM
Goncalves JoanaChief Medical OfficerJun 23 '23Sale3.512,7239,55853,681Jun 27 04:07 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Jun 23 '23Sale3.512,4838,71588,563Jun 27 04:09 PM
Posner ChristopherPresident and CEOMay 05 '23Sale4.403,86917,024172,514May 09 04:22 PM